All Posts by Date or last 15, 30, 90 or 180 days.
also by Lloyd: and

Links on this site earn me fees or commissions.
As an Amazon Associate I earn from qualifying purchases @AMAZON

Designed for the most demanding needs of photographers and videographers.
The fastest, toughest, and most compatible portable SSD ever with speeds up to 2800MB/s.

WSJ: Is Fluvoxamine the Covid Drug We’ve Been Waiting For?

re: ethics in medicine

Another promising drug, to be suppressed at all costs by your government?

Because if Fluvoxamine works, Big Pharma would spend billions to generate as much FUD as possible—it would generate trillions of dollars of future profits. They will buy off the CDC, FDA, NIH as they always have**.

* FUD = Fear, Uncertainty, Doubt.
** For the idiots and children reading this, there are many ways to buy-off officials besides the idiot’s method of cash payments.

WSJ: Is Fluvoxamine the Covid Drug We’ve Been Waiting For?

2021-12-28, By Allysia Finley. Emphasis added.

A 10-day treatment costs only $4 and appears to greatly reduce symptoms, hospitalization and death.

The Food and Drug Administration last week authorized two oral antiviral medicines for the early treatment of Covid-19. But don’t get too excited. The U.S. will still have a meager treatment arsenal this winter...

Yet a promising alternative isn’t getting its due: fluvoxamine, a pill the FDA approved in 1994 to treat obsessive-compulsive disorders. Doctors often prescribe it off-label for anxiety, depression and panic attacks. Studies show that fluvoxamine is highly effective at preventing hospitalization in Covid-infected patients, and it’s unlikely to be blunted by Omicron.

Doctors hypothesize that fluvoxamine can trigger a cascade of reactions in cells that modulate inflammation and interfere with virus functions. It could thus prevent an overreactive immune response to pathogens—what’s known as a cytokine storm—that can lead to organ failure and death. It also increases nighttime levels of melatonin—the hormone that makes you sleepy—which evidence suggests can also mitigate inflammation


Researchers at McMaster University in Hamilton, Ontario, last winter launched a large clinical trial in Brazil. The results from their trial, published in the Lancet in October, were stunning: Fluvoxamine reduced the odds of hospitalization or emergency care by 66% and death by 90% among unvaccinated high-risk patients who mostly followed the treatment regimen—comparable to monoclonal antibodies. There was no difference in adverse effects between the fluvoxamine and placebo groups.

While the FDA doesn’t need to grant fluvoxamine emergency-use authorization for doctors to prescribe it, some may be reluctant to do so unless the NIH recommends it in its Covid-19 treatment guidelines. Physicians have been investigated by state medical boards for prescribing the antiparasite Ivermectin off-label for Covid-19.

The NIH states that “there is insufficient evidence . . . to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.” It wants evidence from another large clinical trial. Yet the U.S. is recording nearly as many deaths from Covid-19 today as when Dr. Collins made his statement in March. If the NIH doesn’t budge, states could enact laws that protect doctors who prescribe fluvoxamine, They could also order doses to administer to patients, which would cost little but could save many lives.

WIND: at least one of newly authorized drugs for COVID is very dangerous (drug interactions), but they will make Big Pharma a lot of money. They were quickly authorized because of (no, not the science)... follow the money.

Fluvoxamine might work well or it might not work as well as these initial studies suggest, and it might not work at all. But it is beyond stupid (vicious and evil?) to not run some large-scale test—the drug is cheap and readily available. And if it cuts anxiety, that’s just the ticket for COVID terrorism?!

Follow the money predicts that at the least Fluvoxamine will be ignored, but already it is being actively discouraged with a massive “hammer”—few doctors would want to be investigated by state medical boards! But the reality is that most doctors work for big medical organizations, and can be harrassd and fired for stepping out of line. So there is MASSIVE pressure on most doctors to not consider things outside the official guidelines.

But follow the money tells us that you can COUNT on the FDA/NIH/CDC to discourage its use. It’s as easy as calling it “unproven” and making sure that it is not an “approved treatment”. Poof! It’s no longer viable for most doctors.

The Lancet: Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial


This is, to the best of our knowledge, the first large, randomised controlled trial to test the efficacy of fluvoxamine for acute treatment of COVID-19. We found a clinically important absolute risk reduction of 5·0%, and 32% RR reduction, on the primary outcome of hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19, consequent on the administration of fluvoxamine for 10 days. This study is only the second study to show an important treatment benefit for a repurposed drug in the early treatment population.13 Our findings represent the complete analysis of the trial after the DSMC recommended stopping the active fluvoxamine group and all 28-day follow-up of randomly assigned patients. Given fluvoxamine's safety, tolerability, ease of use, low cost, and widespread availability, these findings might influence national and international guidelines on the clinical management of COVID-19.


WIND: an absolute risk reduction of 5.0% is remarkably high. Tens of millions of people take statins for an absoute risk reduction of less than 1%.

View all handpicked deals...

Pentax 8x43 Z-Series ZD ED Binoculars
$849 $699
SAVE $150 | Terms of Use | PRIVACY POLICY
Contact | About Lloyd Chambers | Consulting | Photo Tours
Mailing Lists | RSS Feeds | Twitter
Copyright © 2020 diglloyd Inc, all rights reserved.
Display info: __RETINA_INFO_STATUS__